ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage
ACST
-1.84%
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually giving an update on the use of its “at the market” equity providing plan.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering system under which Acasti may issue and sell from time to time its everyday shares having an aggregate offering price of up to $75 million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions found on January 27, 2021, Acasti granted an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares had been sold at prevailing market costs averaging US$1.0747 a share. No securities had been offered through the facilities of the TSXV or perhaps, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with the services of theirs. As a result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and often will supply the Company with extra freedom in its ongoing review process to check out and evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, development and commercialization of prescription drugs using OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of safety as well as efficacy in lowering triglycerides in people with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being formulated for individuals with severe HTG.
Forward Looking Statements – ACST Stock
Statements of this press release that are not statements of historical or current fact constitute “forward looking information” within the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking statements include known and unknown risks, uncertainties, along with other unknown elements that may cause the particular outcomes of Acasti to be materially different from historical results and even as a result of any future outcomes expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe these kinds of risks as well as uncertainties, readers are actually urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other similar expressions to be forward-looking and uncertain. Readers are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the date of this press release. Forward-looking claims in that press release include, but are not restricted to, statements or info about Acasti’s strategy, future operations and its review of strategic alternatives.
The forward looking claims found in this press release are expressly qualified in their entirety by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” section found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor aisle of Acasti’s site at www.acastipharma.com. All forward-looking statements in that press release exist as of the particular date of this press release.
ACST Stock – Acasti doesn’t undertake to redesign some such forward looking statements whether as a consequence of information that is brand new , future events or perhaps otherwise, except as called for by law. The forward-looking claims contained herein are also subject typically to assumptions and risks and uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is giving an update on the usage
